Prema P Peethambaram MD Associate Professor

PubMed

• Prognostic Value of Exercise Stress Echocardiography for Patients With Breast Cancer Treated With Chest Radiotherapy.
  Rafael E Toro Manotas, Mariana Garcia Arango, Renzo J Mogollon, Jamie L Carroll, Jenna E Hoppenworth
  JACC. Advances. 2025-10-01
• Assessing double product derived from stress echocardiography as a prognostic indicator of major adverse cardiac events in patients with breast cancer treated with rad...
  Juan Manuel Garzon-Dangond, Maria F Gomez Ardila, Eduardo Tellez Garcia, Andres E Daryanani, Prema P Peethambaram
  Cardio-Oncology. 2025-06-13
• 1 citations
  Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience.
  Nusrat Jahan, Jodi Taraba, Nicholas J Boddicker, Karthik V Giridhar, Roberto A Leon-Ferre
  Clinical Breast Cancer. 2025-04-01

Journal Articles

• Soyfood consumption in breast cancer survivors: Don't overstate the facts!  
  Peethambaram P, Olson J, Loprinzi CL, Oncology, 1/1/2013
• Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival  
  Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duv..., Ann Oncol, 4/1/1999
• Toxicity of systemic adjuvant chemotherapy for colorectal cancer  
  Peethambaram PP, O'Connell MJ, Seminars in Colon & Rectal Surgery, 1/1/1996

Books/Book Chapters

• Supportive Care in Cancer: A Handbook for Oncologists 
  Chapter: Management of cancer anorexia and cachexia. 
  Page 297 - 308Peethambaram PP, Loprinzi CLEditors: Klastersky J, et al.Marcel Dekker, Inc., New York, NYEdition 2nd,1999
• Principles and Practice of Supportive Oncology 
  Chapter: Cancer anorexia/cachexia. 
  Page 133 - 139Loprinzi CL, Goldberg RM, Peethambaram PPEditors: Berger A, et al.Lippincott-Raven Publishers, Philadelphia1998

Abstracts/Posters

• Phase i dose-escalation and drug interaction study of abt-888 (parp1 inhibitor) and topotecan (topoisomerase I inhibitor) in patients with advanced cancer.
  Boakye-Agyeman F, Reid J, Menefee M, Buhrow S, Walden C, Piens J, Kayode O, Erlichman C, Haluska P, Northfelt DW, Kaufmann SH, Ames M, Satele DV, Tang H, Peethambaram ..., Clin Pharmacol Ther, 3/1/2014
• Results from two phase 1 trials of HER2/NEU-directed active cellular immunotherapy in patients with advanced malignancies.
  Sims RB, Park JW, Peethambaram PP, Melisko M, Rinn KJ, Alberts SR, Provost NM, Ann Oncol, 10/1/2010
• Phase II trial of lapatinib in combination with weekly topotecan in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
  Haluska P, Oberg AL, Dakhil SR, Ziegler KLA, Rowland KM, Hartmann LC, Moore DF, Keeney GL, Peethambaram PP, Ann Oncol, 5/1/2009

Lectures

• Androgens and anti-androgens to treat breast cancer. 
  Rochester, MN - 3/1/2013
• The "pain" truth about aromatase inhibitors. 
  Rochester, MN - 5/1/2012
• "Journal club" 
  Rochester, MN - 8/1/2011